Palonosetron

Palonosetron
Klinički podaci
Prodajno ime	Aloxi, Onicit
Drugs.com	Monografija
Način primene	Intravenozno
Farmakokinetički podaci
Poluvreme eliminacije	40 h
Identifikatori
CAS broj	119904-90-4
ATC kod	A04AA05 (WHO)
PubChem	CID 148211
DrugBank	DB00377
ChemSpider	130656
ChEMBL	CHEMBL1189679
Hemijski podaci
Formula	C19H24N2O
Molarna masa	296,407
	SMILES [H][C@@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2; ;
	InChI InChI=1S/C19H24N2O/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20/h2,4,6,13,15,17H,1,3,5,7-12H2/t15-,17+/m0/s1 ; Key:CPZBLNMUGSZIPR-DOTOQJQBSA-N ;

Palonosetron je organsko jedinjenje, koje sadrži 19 atoma ugljenika i ima molekulsku masu od 296,407 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	2
Broj donora vodonika	0
Broj rotacionih veza	1
Particioni koeficijent^[10] (ALogP)	2,7
Rastvorljivost^[11] (logS, log(mol/L))	-3,0
Polarna površina^[12] (PSA, Å²)	23,6

Reference

^ De Leon, A. (октобар 2006). „Palonosetron (Aloxi): A second-generation 5-HT₃ receptor antagonist for chemotherapy-induced nausea and vomiting”. Proceedings (Baylor University. Medical Center). 19 (4): 413—6. PMC 1618755 . PMID 17106506. doi:10.1080/08998280.2006.11928210.
^ Stoltz, R.; Cyong, J. C.; Shah, A.; Parisi, S. (4 May). „Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. And Japanese healthy subjects”. Journal of Clinical Pharmacology. 44 (5): 520—31. PMID 15102873. doi:10.1177/0091270004264641. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Rubenstein, E. B. (мај 2004). „Palonosetron: A unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting”. Clinical Advances in Hematology & Oncology : H&O. 2 (5): 284—9. PMID 16163194.
^ Yang, L. P.; Scott, L. J. (новембар 2009). „Palonosetron: In the prevention of nausea and vomiting”. Drugs. 69 (16): 2257—78. PMID 19852528. doi:10.2165/11200980-000000000-00000.
^ Siddiqui, M Asif A.; Scott, Lesley J. (2004). „Palonosetron”. Drugs. 64 (10): 1125—32. PMID 15139789. doi:10.2165/00003495-200464100-00006.
^ Eisenberg, P.; MacKintosh, F. R.; Ritch, P.; Cornett, P. A.; MacCiocchi, A. (фебруар 2004). „Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: A dose-ranging clinical study”. Annals of Oncology : Official Journal of the European Society for Medical Oncology. 15 (2): 330—7. PMID 14760130. doi:10.1093/annonc/mdh047.
^ Stoltz, R.; Parisi, S.; Shah, A.; MacCiocchi, A. (новембар 2004). „Pharmacokinetics, metabolism and excretion of intravenous l4C-palonosetron in healthy human volunteers”. Biopharmaceutics & Drug Disposition. 25 (8): 329—37. PMID 15378559. doi:10.1002/bdd.410.
^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126. уреди
^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ . doi:10.1021/jp980230o. Недостаје или је празан параметар |title= (помоћ)
^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Palonosetron

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] De Leon, A. (октобар 2006). „Palonosetron (Aloxi): A second-generation 5-HT₃ receptor antagonist for chemotherapy-induced nausea and vomiting”. Proceedings (Baylor University. Medical Center). 19 (4): 413—6. PMC 1618755 . PMID 17106506. doi:10.1080/08998280.2006.11928210.

[2] Stoltz, R.; Cyong, J. C.; Shah, A.; Parisi, S. (4 May). „Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. And Japanese healthy subjects”. Journal of Clinical Pharmacology. 44 (5): 520—31. PMID 15102873. doi:10.1177/0091270004264641. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[3] Rubenstein, E. B. (мај 2004). „Palonosetron: A unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting”. Clinical Advances in Hematology & Oncology : H&O. 2 (5): 284—9. PMID 16163194.

[4] Yang, L. P.; Scott, L. J. (новембар 2009). „Palonosetron: In the prevention of nausea and vomiting”. Drugs. 69 (16): 2257—78. PMID 19852528. doi:10.2165/11200980-000000000-00000.

[5] Siddiqui, M Asif A.; Scott, Lesley J. (2004). „Palonosetron”. Drugs. 64 (10): 1125—32. PMID 15139789. doi:10.2165/00003495-200464100-00006.

[6] Eisenberg, P.; MacKintosh, F. R.; Ritch, P.; Cornett, P. A.; MacCiocchi, A. (фебруар 2004). „Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: A dose-ranging clinical study”. Annals of Oncology : Official Journal of the European Society for Medical Oncology. 15 (2): 330—7. PMID 14760130. doi:10.1093/annonc/mdh047.

[7] Stoltz, R.; Parisi, S.; Shah, A.; MacCiocchi, A. (новембар 2004). „Pharmacokinetics, metabolism and excretion of intravenous l4C-palonosetron in healthy human volunteers”. Biopharmaceutics & Drug Disposition. 25 (8): 329—37. PMID 15378559. doi:10.1002/bdd.410.

[8] Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126. уреди

[9] Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[10] . doi:10.1021/jp980230o. Недостаје или је празан параметар |title= (помоћ)

[11] Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[12] Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]